Checkpoint inhibitors, including anti-CTLA-4 and anti-PD-1/PD-L1 blockers, have changed the treatment landscape for patients with advanced RCC in the past 3 years. The gene discussed is CTLA4; the disease is renal cell adenocarcinoma.